Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Zendy

Steven P. Marso | Zendy; Gilbert H. Daniels | Zendy; Kirstine BrownFrandsen | Zendy; Peter Lommer Kristensen | Zendy; Johannes F.E. Mann | Zendy; Michael A. Nauck | Zendy; Steven E. Nissen | Zendy; Stuart J. Pocock | Zendy; Neil R Poulter | Zendy; Lasse Steen Ravn | Zendy; William M. Steinberg | Zendy; Mette Stockner | Zendy; Bernard Zinman | Zendy; Richard M. Bergenstal | Zendy; John B. Buse | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Author(s) -

Steven P. Marso,

Gilbert H. Daniels,

Kirstine BrownFrandsen,

Peter Lommer Kristensen,

Johannes F.E. Mann,

Michael A. Nauck,

Steven E. Nissen,

Stuart J. Pocock,

Neil R Poulter,

Lasse Steen Ravn,

William M. Steinberg,

Mette Stockner,

Bernard Zinman,

Richard M. Bergenstal,

John B. Buse

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1603827

Subject(s) - liraglutide , medicine , hazard ratio , placebo , myocardial infarction , type 2 diabetes , confidence interval , diabetes mellitus , stroke (engine) , surgery , endocrinology , mechanical engineering , alternative medicine , pathology , engineering

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research